Table 1 Summary of clinical characteristics of patients included in the study.
Number of cases | % | |
|---|---|---|
Gender | ||
male | 22 | 38.6 |
female | 35 | 61.4 |
Age | ||
<1 year | 0 | 0 |
1–5 years | 50 | 87.7 |
6–9 years | 3 | 5.3 |
≥10 years | 4 | 7 |
WBC count (x109/L) | ||
<10 | 16 | 28.1 |
10–50 | 20 | 35.1 |
50–100 | 12 | 21 |
≥100 | 9 | 15.8 |
CNS involvement | ||
negative | 50 | 87.7 |
positive | 4 | 7 |
no data | 3 | 5.3 |
Prednisone response | ||
good | 53 | 93 |
poor | 2 | 3.5 |
no data | 2 | 3.5 |
MRD after induction | ||
MRD-negative | 17 | 29.8 |
MRD-positive | 40 | 70.2 |
no data | 0 | 0 |
MRD after consolidation | ||
MRD-negative | 40 | 70.2 |
MRD-positive | 9 | 15.8 |
no data | 8 | 14 |
MRD-based risk group | ||
MRD-SR | 16 | 28.1 |
MRD-MR | 35 | 61.4 |
MRD-HR | 0 | 0 |
no data | 6 | 10.5 |
Risk group | ||
SR | 15 | 26.3 |
MR | 37 | 64.9 |
HR | 5 | 8.8 |
